Clinical Trial Update: Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 trial from Azevan Pharmaceuticals aims to inhibit aggressive behavior in people with Fragile X syndrome, but the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Snippet

Sponsor: Azevan Pharmaceuticals | Conditions: Aggressive Behavior in Fragile X Syndome | Phase 2 | Status: NOT_YET_RECRUITING